Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database

BACKGROUND: Neoadjuvant therapy (NAT) for T1/T2 pancreatic adenocarcinoma (PDAC) prior to pancreaticoduodenectomy remains controversial. We compared positive margin rates in patients with clinical T1&T2 tumors who did and did not receive NAT. METHODS: The National Cancer Database (NCDB) found cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Greco, Stephanie H., August, David A., Shah, Mihir M., Chen, Chunxia, Moore, Dirk F., Masanam, Monika, Turner, Amber L., Jabbour, Salma K., Javidian, Parisa, Grandhi, Miral S., Kennedy, Timothy J., Alexander, H. Richard, Carpizo, Darren R., Langan, Russell C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807160/
https://www.ncbi.nlm.nih.gov/pubmed/33490937
http://dx.doi.org/10.1016/j.sopen.2020.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807160/
https://www.ncbi.nlm.nih.gov/pubmed/33490937
http://dx.doi.org/10.1016/j.sopen.2020.12.001

Ejemplares similares